[Source: TB Alliance website]
TB Alliance announced that on December 1, 2020, the first dose was administered to a patient as part of a new Phase 1 study of its novel compound TBAJ-587 in healthy adult volunteers. New treatment options are urgently needed, especially as there is growing resistance to available drugs to treat tuberculosis (TB).
Further development and design of the Phase 1 study has been undertaken by the ERA4TB project in partnership with TB Alliance. Phase 1 study participants are receiving treatment in the Netherlands, through QPS Netherlands, an IMI partner. QPS Holdings LLC is a global clinical research organization (CRO) specializing in discovery, preclinical and clinical drug development research. The Ministry of Foreign Affairs in the Netherlands also supports the work of TB Alliance and the advancement of TB research and drug development.
Read full news on TB Alliance website.
